Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term use. Found 12 abstracts

Schmier J, Ogden K, Nickman N, Halpern MT, Cifaldi M, Ganguli A, Bao Y, Garg V. Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting. Clinical therapeutics. 2017 Aug;39(8):1600-17.
Hochster HS, Uboha N, Messersmith W, Gold PJ, O Neil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan;75(1):17-23.
Martin JM, Handorf EA, Kutikov A, Uzzo RG, Bekelman JE, Horwitz EM, Smaldone MC. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. Cancer. 2014 Jul 15;120(14):2114-21.   PMCID: 4429530
Mateo J, Berlin J, de Bono JS, Cohen RB, Keedy V, Mugundu G, Zhang L, Abbattista A, Davis C, Gallo Stampino C, Borghaei H. A first-in-human study of the anti-alpha5beta1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Nov;74(5):1039-46.   PMCID: Pmc4209234
Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006 Sep 10;24(26):4324-32.
Lauritsen JP, Haks MC, Lefebvre JM, Kappes DJ, Wiest DL, Chen X, Arciero CA, Godwin AK, Barsevick AM, Whitmer K, Nail LM, Beck SL, Dudley WN, Weiner LM, Treat J. Role of the transcription factor Th-POK in CD4:CD8 lineage commitment. . Immunological reviews. 2006 Feb;209(2):237-52.
Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D, Johnson DH. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. Journal of the National Cancer Institute. 2002 Feb 06;94(3):173-81.
Langer CJ. The emerging world role of irinotecan in lung cancer. Oncology (Huntingt). 2001 Jul;15(7 Suppl 8):15-21.
Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000 Jun;77(3):446-9.
Ozols RF. The role of gemcitabine in the treatment of ovarian cancer. Semin Oncol. 2000 Feb;27(1 Suppl 2):40-7.
Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000 Jul;18(14):2780-7.
Ross EA, Moore D. Modeling clustered, discrete, or grouped time survival data with covariates. Biometrics. 1999 Sep;55(3):813-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term use

use therapeutic drug therapy therapeutic use Female Aged administration & dosage Human adverse effects Male Antineoplastic Combined Chemotherapy Protocols Middle Aged Survival Analysis pathology Adult US Gov't Support-PHS Treatment Outcome 80 and over Aged Intravenous Infusions Antineoplastic Agents Lung Neoplasms metabolism analogs & derivatives United States Non-US Gov't Support economics Paclitaxel Monoclonal Antibodies statistics & numerical data Drug Dose-Response Relationship Deoxycytidine adverse Ovarian Neoplasms Disease-Free Survival Middle Age effects Monoclonal Antibodies-Humanized immunology genetics Camptothecin surgery Cisplatin pharmacokinetics Antineoplastic Antimetabolites Clinical Trials radiotherapy Non-Small-Cell Lung Carcinoma Drug Administration Schedule Cohort Studies Neoplasms Statistical Data Interpretation Randomized Controlled Trials Japan 103882-84-4 (gemcitabine) therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols Kidney Failure analogs & Flushing MAP Kinase Kinase Kinases Retrospective Studies prostatic neoplasms Random Allocation Biometry Antirheumatic Agents Liver Function Tests Hospital Costs Colorectal Neoplasms Prognosis Neoplasm Drug Resistance Bilirubin Phytogenic Antineoplastic Agents brachytherapy Predictive Value of Tests Genetic Engineering Diabetic Retinopathy derivatives Rituximab Protein Kinase Inhibitors Cost-Benefit Analysis hospital costs Suburban Population Urban Population Monoclonal) 0 (Antibodies monoclonal Proto-Oncogene Proteins diagnosis therapeutic use MH - Clinical Tr Light Coagulation 0 (Antineoplastic Combined Chemotherapy Protocols) Topotecan Mutation chemically induced Quality of Life Educational Status physiology clinical practice patterns Squamous Cell Carcinoma Linear Models Fatigue Neoplasm Proteins humanized Dimerization epidemiology Topoisomerase I Inhibitors Hypotension Integrin alpha5beta1 Cluster Analysis Likelihood Functions Drug Synergism blood Non-Small-Cell Lung therapeutic use MH - Carcinoma Area Under Curve Rural Population Non-US Gov't Research Support Breast Neoplasms Infliximab Aging infliximab drug therapy MH - Cisplatin Prostatectomy 951-77-9 (Deoxycytidine) Metabolic Clearance Rate Prostatic Neoplasms Registries Biological Models ras Proteins Health Insurance Biological Tumor Markers Drug Tolerance rituximab Benzimidazoles Physician's Practice Patterns Liver Diseases erbB-2 Receptor utilization Blindness trends 0 (bevacizumab) Aspartate Aminotransferases Etoposide Neoplasm Staging 15663-27-1 (Cisplatin) NIH Research Support-Extramural Statistical Models antagonists & inhibitors arthritis Factual Databases Mice Nausea Home Infusion Therapy
Last updated on Sunday, July 12, 2020